Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Eli Lilly and Co LLY

Healthcare
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of a4ß7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).


NYSE:LLY - Post by User

Eli Lilly and Co
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(232)
•••
Post by whytestockson Jul 18, 2024 5:46am
121 Views
Post# 36137855

Will Eli Lilly Do a Stock Split in 2024?

Will Eli Lilly Do a Stock Split in 2024?
News; $LLY Will Eli Lilly Do a Stock Split in 2024?2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...LLY - Will Eli Lilly Do a Stock Split in 2024?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities